regeneron glp-1 GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates Announcing an in-licensing agreement for
Description
Metabolic Effects Beyond Weight Loss Both medication types improve metabolic markers, but dual agonists might offer some advantages in certain areas
Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss
Beyond dietary modifications, several lifestyle strategies can help reduce bloating associated with GLP-1 medications
Your personalized weight loss plan is built around your goals, hormonal profile, and overall health as a woman
Provider and patient attitudes vary, but there exists much more reluctance to initiate pharmacotherapy for obesity than for other chronic diseases such as hypertension, type 2 diabetes, or hyperlipidemia
118 Additionally, Ma et al
